drugset

drugset / Trial / NCT01739582

An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism

NCT01739582 ↗

Phase 3 Completed 300 enrolled Repros Therapeutics Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine the safety profile of Androxal in men with secondary hypogonadism.

Timeline

Start: 2012-11
Primary completion: 2014-04
Completion: 2014-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Androxal	Unknown	25 mg	Oral

Indications